Study drug LOXO-101 shows tumor regression in varied cancers

(University of Texas M. D. Anderson Cancer Center) A phase I study of the drug LOXO-101 appears to significantly reduce tumors in patients with varied types of genetically defined cancer, according to a study led by The University of Texas MD Anderson Cancer Center.